Clinical Testing News and Research

RSS

Novel graphene oxide-based biosensor may speed up development of new drugs against HIV, cancer

Longing to find a cure for cancer, HIV and other yet incurable diseases, researchers have already tried out hundreds of drugs, each requiring preclinical and clinical testing with live subjects. How many chemical agents more to try? Moving at such rate, will we find the cure during our lifetime? One of the easiest ways to speed up the drug development process is to simply perform it outside of the living body (e.g., by watching the substances react with the smallest pieces of live tissue and thus quickly predicting the overall effect it will make to the body when inside).

23 Sep 2015

Shire and Sangamo revise agreement to expedite development of ZFP Therapeutics for Huntington's disease, hemophilia A and B

Sangamo BioSciences, Inc., a leader in therapeutic genome editing, announced today that the company and its collaborator, Shire plc, have agreed to revise their January 2012 collaboration and license agreement to expedite the development of ZFP Therapeutics for hemophilia A and B and Huntington's disease.

2 Sep 2015

Gene therapy restores visual function in mouse model of LCA1

Mice lacking the protein retGC1, which is deficient in humans suffering Leber congenital amaurosis-1 (LCA1), a disorder that causes severe visual impairment beginning in infancy, received gene therapy to replace retGC1 and showed fully restored visual function that persisted for at least 6 months.

1 Sep 2015

Sigma-Aldrich signs agreement with PHE to manufacture, supply bacterial and fungal NCTC/NCPF CRMs

Sigma-Aldrich Corporation, a leading Life Science and Technology Company, today announced it has signed an agreement with Public Health England to manufacture and supply bacterial and fungal NCTC/NCPF Certified Reference Materials (CRM) in LENTICULE disc format worldwide for use as controls in food, water, environmental and clinical testing microbiology laboratories.

27 Aug 2015

UH research points to promising target in treatment of pancreatic cancer

Pancreatic cancer is extremely deadly and often has a poor prognosis. Ranked as the fourth deadliest cancer in the U.S. and poised to move up within the next few years, pancreatic cancer is very difficult to detect in its early stages. Seldom diagnosed early and typically spreading rapidly, the disease has no effective treatment once it advances.

26 Aug 2015

Tocagen's Toca 511 & Toca FC receives FDA orphan drug designation for treatment of glioblastoma

Tocagen Inc., a clinical-stage immuno-oncology company, today announced that the U.S. Food and Drug Administration has granted orphan drug designation to the company's lead immuno-oncology product candidate, Toca 511 & Toca FC, for the treatment of glioblastoma.

26 Aug 2015

Kuros Biosurgery closes financing round of CHF15M

Kuros Biosurgery AG, a biotechnology company developing novel biomaterials and bioactive-biomaterial combination products and focused in therapeutic areas covering sealants and orthobiologics, announced today that it has closed a financing round of CHF15M. An additional investment is expected in a second closing later this year.

18 Aug 2015

Bionik Laboratories reports net loss for second quarter 2015

Bionik Laboratories Corp., a pioneering medical device and robotics company developing technologies and solutions for individuals with neurological disorders, announced today its financial results for the quarter ended June 30, 2015.

17 Aug 2015

CRI to honor three scientists for contributions to immunology and cancer immunotherapy research

The Cancer Research Institute, a nonprofit organization dedicated to fueling the discovery and development of immunotherapies for all forms of cancer, will bestow its highest honors on three scientists who have made fundamental contributions to the fields of immunology and cancer immunotherapy.

10 Aug 2015

California Initiative to Advance Precision Medicine selects two demonstration projects

Two demonstration projects that aim to yield quick results for patients have been selected by the new California Initiative to Advance Precision Medicine, a public-private effort launched by Governor Edmund G. Brown Jr.

4 Aug 2015

KalVista raises $33 million in Series B financing to support development of plasma kallikrein inhibitors

KalVista Pharmaceuticals, a research-led pharmaceutical company, today announced it has raised $33 million in a Series B financing to support its research and clinical development programs. KalVista will use the funds to advance its proprietary portfolio of plasma kallikrein inhibitors for treating diabetic macular edema (DME) and hereditary angioedema (HAE).

22 Jul 2015

Resveratrol and quercetin may improve efficacy of existing chemotherapeutic cancer drug

Resveratrol and quercetin, two polyphenols that have been widely studied for their health properties, may soon become the basis of an important new advance in cancer treatment, primarily by improving the efficacy and potential use of an existing chemotherapeutic cancer drug.

17 Jul 2015

Protagonist Therapeutics closes $40 million Series C financing

Protagonist Therapeutics, Inc., a company developing novel, orally stable peptide therapeutics for gastrointestinal diseases and disorders, today announced the closing of a $40 million Series C financing.

16 Jul 2015

Quotient Clinical acquires second GMP manufacturing facility, expands pharmaceutical sciences capabilities

Quotient Clinical, the Translational Pharmaceutics Company, has announced a significant expansion of its pharmaceutical sciences capabilities, doubling capacity through the acquisition of a second GMP manufacturing facility and the construction of new formulation development and pharmaceutical analysis laboratories.

14 Jul 2015

New research identifies potential treatment for primary effusion lymphoma

New research from the University of Southern California Norris Comprehensive Cancer Center has identified a potential treatment for a rare but previously incurable form of lymphoma that is observed primarily in patients with HIV/AIDS infection.

8 Jul 2015

Aridis expands, accelerates current AR-301 Phase 2a study for treatment of acute pneumonia in the U.S.

Aridis Pharmaceuticals, Inc., a biopharmaceutical company applying proprietary technologies to produce novel anti-infectives and immunotherapies for infectious diseases, announced today that the U.S. Food and Drug Administration has accepted its Investigational New Drug (IND) application for AR-301, also referred to as Salvecin, the company's fully human anti-Staphylococcal α-toxin IgG1 monoclonal antibody being developed for the treatment of hospital-acquired and ventilator-associated pneumonia (HAP and VAP) caused by Staphylococcus aureus, including multi-drug resistant 'MRSA' strains.

8 Jul 2015

CSRO survey reveals rheumatologists have concerns about biosimilars approval process

The Coalition of State Rheumatology Organizations (CSRO), a nationwide group of state and regional professional rheumatology societies, today released the findings of a national survey of rheumatologists that explored perceptions of biosimilars and the potential impact of these new drugs on patients.

2 Jul 2015

Kalorama Information: NGS diagnostics can detect any number of genetic variants

Next generation sequencing may be able to bypass some of the downside of molecular testing and in doing so earn its place in clinical testing, according to Kalorama Information.

30 Jun 2015

CTI Biotechnology implements Xybion's Pristima 7 Preclinical Suite

Xybion Corporation, leading provider of preclinical R&D solutions announced today that CTI Biotechnology in Suzhou, China has implemented Xybion's Pristima 7 Preclinical Suite. Pristima® was selected after an exhaustive evaluation of top selling preclinical software systems on the market.